EUVIMEDEUVIMED entdecken
Übersichtsarbeit

UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis

Fernando Bessone, Geraldine L Hillotte, Natalia Ahumada, Fernanda Jaureguizahar, Anabela C Medeot, Marcelo G Roma

Seminars in Liver Disease · 2024-02 · 44 (01) · 001-022

DOI: 10.1055/s-0044-1779520 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, online erschienen am 20.02.2024. Verfasst von Fernando Bessone und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Provincial del Centenario, Facultad de Ciencias Médicas, Servicio de Gastroenterología y Hepatología, Universidad Nacional de Rosario, Rosar…. Hauptthemen laut MEDLINE: Cholestasis, Liver Diseases, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 174 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced liver injury (DILI) is an adverse reaction to medications and other xenobiotics that leads to liver dysfunction. Based on differential clinical patterns of injury, DILI is classified into hepatocellular, cholestatic, and mixed types; although hepatocellular DILI is associated with inflammation, necrosis, and apoptosis, cholestatic DILI is associated with bile plugs and bile duct paucity. Ursodeoxycholic acid (UDCA) has been empirically used as a supportive drug mainly in cholestatic DILI, but both curative and prophylactic beneficial effects have been observed for hepatocellular DILI as well, according to preliminary clinical studies. This could reflect the fact that UDCA has a plethora of beneficial effects potentially useful to treat the wide range of injuries with different etiologies and pathomechanisms occurring in both types of DILI, including anticholestatic, antioxidant, anti-inflammatory, antiapoptotic, antinecrotic, mitoprotective, endoplasmic reticulum stress alleviating, and immunomodulatory properties. In this review, a revision of the literature has been performed to evaluate the efficacy of UDCA across the whole DILI spectrum, and these findings were associated with the multiple mechanisms of UDCA hepatoprotection. This should help better rationalize and systematize the use of this versatile and safe hepatoprotector in each type of DILI scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholestasisLiver DiseasesChemical and Drug Induced Liver InjuryHumansUrsodeoxycholic AcidNecrosisLiver

Substanzen

Ursodeoxycholic Acid

Autor:innen und Institutionen

  • Hospital Provincial del Centenario, Facultad de Ciencias Médicas, Servicio de Gastroenterología y Hepatología, Universidad Nacional de Rosario, Rosario, Argentina.
  • Instituto de Fisiología Experimental (IFISE-CONICET), Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.

Zitieren

APA

Bessone, F., Hillotte, G. L., Ahumada, N., Jaureguizahar, F., Medeot, A. C., & Roma, M. G. (2024). UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis. Seminars in Liver Disease, 44(01), 001-022. https://doi.org/10.1055/s-0044-1779520

Vancouver

Bessone F, Hillotte GL, Ahumada N, Jaureguizahar F, Medeot AC, Roma MG. UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis. Seminars in Liver Disease. 2024;44(01):001-022. doi:10.1055/s-0044-1779520

BibTeX
@article{Bessone2024,
  author = {Bessone, Fernando and Hillotte, Geraldine L and Ahumada, Natalia and Jaureguizahar, Fernanda and Medeot, Anabela C and Roma, Marcelo G},
  title = {UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis},
  journal = {Seminars in Liver Disease},
  year = {2024},
  volume = {44},
  number = {01},
  pages = {001--022},
  doi = {10.1055/s-0044-1779520}
}
Kostenlos starten →